ESLA Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
2.1M
-9.1%
2.3M
+273.8%
613.2K
-87.2%
4.8M
-13.4%
5.5M
R&D
1.4M
-0.0%
1.4M
+5409.9%
25.4K
-99.4%
4.2M
-10.9%
4.7M
SG&A
684.0K
-23.3%
891.8K
+51.7%
587.8K
-9.4%
648.5K
-26.6%
883.7K
Operating Income
-2084247
+9.1%
-2292064
-273.8%
-613199
+87.2%
-4801149
+13.4%
-5544028
EBITDA
-2084247
+9.1%
-2292064
-273.8%
-613199
+87.2%
-4801149
+13.4%
-5544028
Net Income
-2306339
-0.6%
-2292064
-273.8%
-613174
+87.2%
-4801149
+13.4%
-5544878
EPS (Basic)
$-0.05
+0.0%
$-0.05
-150.0%
$-0.02
+84.6%
$-0.13
+13.3%
$-0.15
EPS (Diluted)
$-0.05
+0.0%
$-0.05
-150.0%
$-0.02
+84.6%
$-0.13
+13.3%
$-0.15
Shares (Diluted)
43.0M
+2.1%
42.1M
+11.3%
37.8M
+2.0%
37.1M
+2.6%
36.2M
Estrella Immunopharma (ESLA) โ€” Financials